What the Research Actually Shows
Chronic pain is the most common reason patients enroll in medical marijuana programs across the United States, and it is also the condition with the most research behind it. A 2025 living systematic review conducted for the Agency for Healthcare Research and Quality (AHRQ) and hosted on the National Institutes of Health's NCBI Bookshelf found moderate evidence that cannabis-based products can produce a meaningful reduction in pain intensity, particularly the emotional or "affective" component of pain, along with modest improvements in physical function and sleep quality for a subset of patients with chronic pain.
This builds on the 2017 National Academies of Sciences, Engineering, and Medicine report, which concluded there was substantial evidence that cannabis is effective for treating chronic pain in adults. The Centers for Disease Control and Prevention (CDC) notes that people in states with medical cannabis programs report using cannabis alongside, or sometimes instead of, other pain treatments, though it emphasizes that research on long-term outcomes is still developing.
THC, CBD, and Why the Ratio Matters
Researchers group cannabis products by their ratio of THC (tetrahydrocannabinol) to CBD (cannabidiol) because the two compounds behave differently in the body. THC is the primary compound responsible for pain-relieving (analgesic) effects in most studies, but it is also the compound responsible for the "high" and carries a higher risk of dependence and cannabis use disorder with regular use. Low-THC or CBD-dominant products generally show less consistent pain relief in controlled studies, though many patients report subjective benefit.
- High-THC products: more consistent analgesic effect, higher risk of intoxication, tolerance, and dependence.
- Balanced THC:CBD products: the ratio most frequently studied in clinical pain trials.
- CBD-only or low-THC products: weaker evidence for direct pain relief, generally lower abuse potential.
Where the Evidence Is Weaker
It is important to be precise about what "moderate evidence" means: it does not mean cannabis works for everyone, and it does not mean it works as well as, or better than, existing pain treatments in every case. Study quality varies widely, follow-up periods are often short, and many trials are small. The AHRQ review and related PubMed-indexed analyses also flag real harms associated with cannabinoids, including the potential for use disorder, withdrawal symptoms on cessation, cognitive effects, and interactions with other medications. Patients considering cannabis for pain should not view it as risk-free simply because it is plant-derived.
How State Medical Programs Treat Chronic Pain
Chronic pain (sometimes listed as "severe pain," "intractable pain," or tied to a specific diagnosis such as neuropathy or back pain) is a qualifying condition in the large majority of U.S. state medical marijuana programs. Requirements differ by state: some require documentation that standard treatments, such as physical therapy or non-opioid medications, have been tried first, while others require a specific diagnosis from a qualified physician. Because state law and federal law remain in conflict — cannabis is still a Schedule I substance under federal law — patients should check their own state's health department website for current qualifying-condition lists and registration steps.
Cannabis and Opioid Use: An Unresolved Question
One argument frequently made in favor of medical cannabis for pain is that it could help some patients reduce their reliance on opioid painkillers. Some earlier observational studies found associations between medical cannabis availability and lower opioid prescribing or overdose rates at the population level. However, more recent and more rigorous research, including analyses cited by the CDC, has not consistently confirmed that cannabis access reduces opioid overdose deaths, and some newer state-level studies have found no protective association or even the opposite. This is an area where the evidence has shifted over time and remains genuinely unsettled, so patients should not assume cannabis is a proven substitute for prescribed pain medication without their doctor's involvement.
Practical Considerations for Patients
- Cannabis-based pain relief is not FDA-approved for chronic pain in the way a prescription drug is; whole-plant products sold through state dispensaries are not federally regulated for consistency or purity the way pharmaceuticals are.
- Two cannabinoid-based prescription drugs (dronabinol and nabilone) are FDA-approved, but for chemotherapy-related nausea, not chronic pain specifically.
- Drug interactions are possible, particularly with blood thinners, sedatives, and other centrally acting medications.
- Older adults and people with a personal or family history of psychosis or substance use disorder face higher risk from THC-containing products.
Medical Disclaimer
This article is for general educational purposes only and is not medical advice. It does not diagnose, treat, or cure any condition, and it is not a substitute for a consultation with a licensed physician or other qualified healthcare provider. Anyone considering medical marijuana for chronic pain should discuss the potential risks, benefits, and interactions with their own doctor and review their state's specific medical marijuana program requirements before making any treatment decision.